-
公开(公告)号：US20070269444A1
公开(公告)日：2007-11-22
申请号：US11574091
申请日：2005-08-23
IPC分类号： A61K39/395 , A61P35/00 , C07K16/18
CPC分类号： C07K16/303 , A61K2039/505 , C07K2317/73
摘要： The present invention provides an anti-cancer agent comprising anti-glypican 3 antibody wherein the anti-cancer agent is administered after a cancer treatment, Preferably, after a cancer treatment is after a treatment for liver cancer, and the treatment for liver cancer is in particular a resection of liver cancer cells. The anti-cancer agent according to the present invention is preferably administered if glypican 3 is expressed in the resected liver cancer cells. The anti-glypican 3 antibody is preferably a monoclonal antibody. The anti-cancer agent according to the present invention is useful for preventing cancer and for preventing the recurrence of cancer.
摘要翻译： 本发明提供了包含抗磷脂酰肌醇蛋白聚糖3抗体的抗癌剂，其中抗癌剂在癌症治疗后施用，优选在癌症治疗后经肝癌治疗后，肝癌治疗为 特别是切除肝癌细胞。 如果在切除的肝癌细胞中表达磷脂酰肌醇蛋白聚糖3，则优选施用本发明的抗癌剂。 抗磷脂酰肌醇蛋白聚糖3抗体优选为单克隆抗体。 根据本发明的抗癌剂可用于预防癌症和预防癌症复发。
-
公开(公告)号：US07871613B2
公开(公告)日：2011-01-18
申请号：US11574091
申请日：2005-08-23
IPC分类号： A61K39/395 , A61K39/00 , C07K16/00 , C12P21/08
CPC分类号： C07K16/303 , A61K2039/505 , C07K2317/73
摘要： The present invention provides an anti-cancer agent comprising anti-glypican 3 antibody wherein the anti-cancer agent is administered after a cancer treatment, Preferably, after a cancer treatment is after a treatment for liver cancer, and the treatment for liver cancer is in particular a resection of liver cancer cells. The anti-cancer agent according to the present invention is preferably administered if glypican 3 is expressed in the resected liver cancer cells. The anti-glypican 3 antibody is preferably a monoclonal antibody. The anti-cancer agent according to the present invention is useful for preventing cancer and for preventing the recurrence of cancer.
摘要翻译： 本发明提供了包含抗磷脂酰肌醇蛋白聚糖3抗体的抗癌剂，其中抗癌剂在癌症治疗后施用，优选在癌症治疗后经肝癌治疗后，肝癌治疗为 特别是切除肝癌细胞。 如果在切除的肝癌细胞中表达磷脂酰肌醇蛋白聚糖3，则优选施用本发明的抗癌剂。 抗磷脂酰肌醇蛋白聚糖3抗体优选为单克隆抗体。 根据本发明的抗癌剂可用于预防癌症和预防癌症复发。
-
公开(公告)号：US20070087005A1
公开(公告)日：2007-04-19
申请号：US11251561
申请日：2005-10-14
申请人： Gregory Lazar , Bassil Dahiyat , Hisafumi Okabe , Masamichi Sugimoto , Shigeyuki Iijima , Izumi Sugo
发明人： Gregory Lazar , Bassil Dahiyat , Hisafumi Okabe , Masamichi Sugimoto , Shigeyuki Iijima , Izumi Sugo
IPC分类号： C07K16/30 , A61K39/395
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/303 , C07K2317/24 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/732
摘要： An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.
摘要翻译： 公开了包含在Fc区中引入的一个或多个氨基酸取代的抗磷脂酰肌醇蛋白聚糖-3抗体。 优选地，在抗磷脂酰肌醇蛋白聚糖-3抗体中，Fc区中位置239,298,326,330和332处的一个或多个氨基酸残基被其它氨基酸残基取代。 由于本发明的Fc修饰的抗磷脂酰肌醇蛋白聚糖-3抗体表现出增强的ADCC活性，因此可用于治疗诸如肝癌的癌症。 还公开了包含本发明的抗磷脂酰肌醇蛋白聚糖-3抗体和药学上可接受的载体的抗癌剂，以及治疗患有癌症的患者的方法，包括向患者施用本发明的抗癌剂。
-
公开(公告)号：US20080267979A1
公开(公告)日：2008-10-30
申请号：US12089957
申请日：2006-10-11
申请人： Gregory Alan Lazar , Bassil I. Dahiyat , Hisafumi Okabe , Masamichi Sugimoto , Shigeyuki Iijima , Izumi Sugo
发明人： Gregory Alan Lazar , Bassil I. Dahiyat , Hisafumi Okabe , Masamichi Sugimoto , Shigeyuki Iijima , Izumi Sugo
IPC分类号： A61K39/395 , C12P21/08 , C07K16/18 , A61P35/00
CPC分类号： C07K16/303 , A61K2039/505 , C07K2317/24 , C07K2317/72 , C07K2317/732
摘要： An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.
摘要翻译： 公开了包含在Fc区中引入的一个或多个氨基酸取代的抗磷脂酰肌醇蛋白聚糖-3抗体。 优选地，在抗磷脂酰肌醇蛋白聚糖-3抗体中，Fc区中位置239,298,326,330和332处的一个或多个氨基酸残基被其它氨基酸残基取代。 由于本发明的Fc修饰的抗磷脂酰肌醇蛋白聚糖-3抗体表现出增强的ADCC活性，因此可用于治疗诸如肝癌的癌症。 还公开了包含本发明的抗磷脂酰肌醇蛋白聚糖-3抗体和药学上可接受的载体的抗癌剂，以及治疗患有癌症的患者的方法，包括向患者施用本发明的抗癌剂。
-
公开(公告)号：US09102739B2
公开(公告)日：2015-08-11
申请号：US12089957
申请日：2006-10-11
申请人： Gregory Alan Lazar , Bassil I. Dahiyat , Hisafumi Okabe , Masamichi Sugimoto , Shigeyuki Iijima , Izumi Sugo
发明人： Gregory Alan Lazar , Bassil I. Dahiyat , Hisafumi Okabe , Masamichi Sugimoto , Shigeyuki Iijima , Izumi Sugo
IPC分类号： C07K16/00 , C12P21/08 , C12P21/06 , A61K39/395 , A61K39/40 , C07K16/30 , C07K1/00 , A61K39/00
CPC分类号： C07K16/303 , A61K2039/505 , C07K2317/24 , C07K2317/72 , C07K2317/732
摘要： An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.
摘要翻译： 公开了包含在Fc区中引入的一个或多个氨基酸取代的抗磷脂酰肌醇蛋白聚糖-3抗体。 优选地，在抗磷脂酰肌醇蛋白聚糖-3抗体中，Fc区中位置239,298,326,330和332处的一个或多个氨基酸残基被其它氨基酸残基取代。 由于本发明的Fc修饰的抗磷脂酰肌醇蛋白聚糖-3抗体表现出增强的ADCC活性，因此可用于治疗诸如肝癌的癌症。 还公开了包含本发明的抗磷脂酰肌醇蛋白聚糖-3抗体和药学上可接受的载体的抗癌剂，以及治疗患有癌症的患者的方法，包括向患者施用本发明的抗癌剂。
-
公开(公告)号：US11124773B2
公开(公告)日：2021-09-21
申请号：US13878181
申请日：2011-10-06
申请人： Tatsumi Yamazaki , Hisafumi Okabe , Shinta Kobayashi , Yu Jau Chen , Atsuhiko Kato , Masami Suzuki , Koichi Matsubara
发明人： Tatsumi Yamazaki , Hisafumi Okabe , Shinta Kobayashi , Yu Jau Chen , Atsuhiko Kato , Masami Suzuki , Koichi Matsubara
摘要： The purpose of the present invention is to provide: a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. For achieving the purpose, the present inventors grew a human cancer tissue repeatedly in a NOG mouse, separated cancer cells from the grown cancer tissue, and made a comparison of various cancer cell culture processes with each other. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process, and consequently the present invention has been accomplished.
-
公开(公告)号：US10018630B2
公开(公告)日：2018-07-10
申请号：US14343364
申请日：2012-09-07
申请人： Tatsumi Yamazaki , Hisafumi Okabe , Shinta Kobayashi , Takeshi Watanabe , Koichi Matsubara , Atsuhiko Kato , Masami Suzuki
发明人： Tatsumi Yamazaki , Hisafumi Okabe , Shinta Kobayashi , Takeshi Watanabe , Koichi Matsubara , Atsuhiko Kato , Masami Suzuki
IPC分类号： G01N33/574 , G01N33/50 , G01N33/569 , C12N5/095 , A61K31/4745 , A61K31/513 , A61K31/555 , A61K31/7088 , A61K39/00 , A61K39/395 , A61K45/06 , C07K16/18 , A61K31/7105 , A61K31/713 , C07K16/30
CPC分类号： G01N33/574 , A61K31/4745 , A61K31/513 , A61K31/555 , A61K31/7088 , A61K31/7105 , A61K31/713 , A61K39/0011 , A61K39/3955 , A61K45/06 , C07K16/18 , C07K16/30 , C12N5/0695 , G01N33/5073 , G01N33/56966 , G01N2500/04
摘要： An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same. The present inventors discovered that highly pure colon cancer stem cells (CSC) can be obtained in a large quantity, and identified two types of states of colon CSCs distinguishable through Lgr5 expression.
-
公开(公告)号：US20120065892A1
公开(公告)日：2012-03-15
申请号：US12759263
申请日：2010-04-13
申请人： Masaaki Oka , Yoshihiko Hamamoto , Hisafumi Okabe
发明人： Masaaki Oka , Yoshihiko Hamamoto , Hisafumi Okabe
IPC分类号： G06F19/00 , G01N33/574 , C12Q1/68 , C40B40/06 , C40B40/10
CPC分类号： G06F19/18 , C12Q1/6809 , C12Q1/6837 , C12Q1/6886 , C12Q2600/118 , G01N33/574 , G06F19/20
摘要： The present invention relates to a scoring system for the prediction of cancer recurrence by selecting genes and/or proteins whose expression patterns associated with recurrence of cancer, and generating formulae with the selected genes and/or proteins for the prediction of cancer recurrence. The present invention relates to a kit for determining the likelihood of recurrence of cancer, comprising DNA chip, oligonucleotide chip, protein chip, peptides, antibodies, probes and primers that are necessary for effecting DNA microarrays, oligonucleotide microarrays, protein arrays, northern blotting, in situ hybridization, RNase protection assays, western blotting, ELISA assays, reverse transcription polymerase-chain reaction to examine the expression of at least 2, 4, 6, 10, 12 or more genes and/or proteins, that are indicative of cancer recurrence.
摘要翻译： 本发明涉及一种用于通过选择与癌症复发相关的表达模式的基因和/或蛋白质预测癌症复发的评分系统，并且与所选择的基因和/或蛋白质产生用于预测癌症复发的公式。 本发明涉及用于确定癌症复发可能性的试剂盒，其包括DNA芯片，寡核苷酸芯片，蛋白芯片，肽，抗体，探针和引物，其用于实现DNA微阵列，寡核苷酸芯片，蛋白质阵列，Northern印迹， 原位杂交，RNA酶保护测定，蛋白质印迹，ELISA测定，逆转录聚合酶链反应以检测至少2,4,6,10,12或更多个表达癌症复发的基因和/或蛋白质的表达 。
-
公开(公告)号：US08655597B2
公开(公告)日：2014-02-18
申请号：US12759263
申请日：2010-04-13
申请人： Masaaki Oka , Yoshihiko Hamamoto , Hisafumi Okabe
发明人： Masaaki Oka , Yoshihiko Hamamoto , Hisafumi Okabe
IPC分类号： G06F7/00
CPC分类号： G06F19/18 , C12Q1/6809 , C12Q1/6837 , C12Q1/6886 , C12Q2600/118 , G01N33/574 , G06F19/20
摘要： The present invention relates to a scoring system for the prediction of cancer recurrence by selecting genes and/or proteins whose expression patterns associated with recurrence of cancer, and generating formulae with the selected genes and/or proteins for the prediction of cancer recurrence. The present invention relates to a kit for determining the likelihood of recurrence of cancer, comprising DNA chip, oligonucleotide chip, protein chip, peptides, antibodies, probes and primers that are necessary for effecting DNA microarrays, oligonucleotide microarrays, protein arrays, northern blotting, in situ hybridization, RNase protection assays, western blotting, ELISA assays, reverse transcription polymerase-chain reaction to examine the expression of at least 2, 4, 6, 10, 12 or more genes and/or proteins, that are indicative of cancer recurrence.
摘要翻译： 本发明涉及一种用于通过选择与癌症复发相关的表达模式的基因和/或蛋白质预测癌症复发的评分系统，并且与所选择的基因和/或蛋白质产生用于预测癌症复发的公式。 本发明涉及用于确定癌症复发可能性的试剂盒，其包括DNA芯片，寡核苷酸芯片，蛋白芯片，肽，抗体，探针和引物，其用于实现DNA微阵列，寡核苷酸芯片，蛋白质阵列，Northern印迹， 原位杂交，RNA酶保护测定，蛋白质印迹，ELISA测定，逆转录聚合酶链反应以检测至少2,4,6,10,12或更多个表达癌症复发的基因和/或蛋白质的表达 。
-
公开(公告)号：US20130288248A1
公开(公告)日：2013-10-31
申请号：US13878181
申请日：2011-10-06
申请人： Tatsumi Yamazaki , Hisafumi Okabe , Shinta Kobayashi , Yu Jau Chen , Atsuhiko Kato , Masami Suzuki , Koichi Matsubara
发明人： Tatsumi Yamazaki , Hisafumi Okabe , Shinta Kobayashi , Yu Jau Chen , Atsuhiko Kato , Masami Suzuki , Koichi Matsubara
IPC分类号： C12N5/095
CPC分类号： C12N5/0695 , G01N33/5011 , G01N33/5073
摘要： The purpose of the present invention is to provide: a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. For achieving the purpose, the present inventors grew a human cancer tissue repeatedly in a NOG mouse, separated cancer cells from the grown cancer tissue, and made a comparison of various cancer cell culture processes with each other. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process, and consequently the present invention has been accomplished.
摘要翻译： 本发明的目的是提供：基本上除去不能形成癌症的细胞的癌干细胞群，其具有再现癌组织的层状结构的特征; 一种生产癌症干细胞团的方法; 并使用癌干细胞团。 为了达到上述目的，本发明人在NOG小鼠中反复生长人类癌组织，从生长的癌组织中分离癌细胞，并进行各种癌细胞培养方法的比较。 结果，可以通过使用不含血清的附着培养方法，连续地制备均质且基本上不含可形成癌细胞的细胞和不能混合形成癌症的细胞的癌干细胞组合物 干细胞培养基而不是通常使用的浮动培养方法，因此本发明已经实现。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.06 秒)
